Lazard Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Lazard Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$551K	Buy	7,421 +6,181	+498%	+$448K	﹤0.01%	1350
2025 Q4	$94.8K	Buy	1,240 +426	+52%	+$28K	﹤0.01%	1751
2025 Q3	$42.3K	Buy	+814	New	+$39.7K	﹤0.01%	1747
2024 Q4	–	Sell	-38	Closed	–	–	2288
2024 Q3	$0	Sell	38 -3,867	-99%	-$102K	﹤0.01%	2268
2024 Q2	$98K	Buy	+3,905	New	+$107K	﹤0.01%	1754
2023 Q2	–	Sell	-12,292	Closed	-$203K	–	2304
2023 Q1	$203K	Sell	12,292 -63,309	-84%	-$738K	﹤0.01%	1310
2022 Q4	$576K	Sell	75,601 -24,076	-24%	-$231K	﹤0.01%	1096
2022 Q3	$990K	Buy	99,677 +74,255	+292%	+$771K	﹤0.01%	990
2022 Q2	$230K	Sell	25,422 -6,455	-20%	-$54K	﹤0.01%	1241
2022 Q1	$323K	Buy	31,877 +12,870	+68%	+$132K	﹤0.01%	1177
2021 Q4	$317K	Buy	19,007 +18,025	+1,836%	+$763K	﹤0.01%	1188
2021 Q3	$46K	Buy	+982	New	+$52.6K	﹤0.01%	1714
2021 Q1	–	Sell	-6,726	Closed	-$478K	–	1856
2020 Q4	$478K	Buy	+6,726	New	+$324K	﹤0.01%	981

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lazard Asset Management's BBIO Position: Q1 2026 in Review

Lazard Asset Management increased its BridgeBio Pharma (BBIO) stake by 498% in Q1 2026, buying an estimated $448K and bringing the position to 7,421 shares worth $551K. The position accounts for ﹤0.01% of the portfolio, ranked #1350.

Lazard Asset Management first reported a position in BBIO in Q4 2020 and has held it in 13 quarters since. The position peaked at $990K in Q3 2022. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Lazard Asset Management held 7,421 shares of BridgeBio Pharma worth $551K as of Q1 2026.
Lazard Asset Management bought 6,181 BridgeBio Pharma shares in Q1 2026, an estimated $448K.
BridgeBio Pharma made up ﹤0.01% of Lazard Asset Management's portfolio in Q1 2026, its #1350 holding.
Lazard Asset Management first reported a position in BridgeBio Pharma in Q4 2020 and has held it in 13 quarters since.
Lazard Asset Management's BridgeBio Pharma position peaked at $990K in Q3 2022.
457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.